# Treatment methods for ovarian cancer
The treatment of ovarian cancer depends strongly on the type of tumor, the stage, genetic characteristics (such as BRCA mutations) and how far the disease has progressed. Most patients undergo a combination of surgery and chemotherapy. After initial treatment, maintenance therapy can extend the time until the disease returns. Upon recurrence, re-treatment may be possible, depending on how long ago the previous chemotherapy was.
Surgery
ProveniIncluded in official guidelines, or approved by EMA or FDA
Surgery is usually the first step and aims to remove as much cancer tissue as possible. In early stages, this involves removal of the affected ovary and fallopian tube; in advanced disease, an attempt is made to remove all visible tumor masses. This is called "cytoreduction".
The procedure varies from laparoscopic (with small incisions) to open surgery, depending on size and spread. Possible side effects include infection, bleeding, bowel injury and long-term pain. Recovery time varies; some patients return to normal activities within weeks, others need months.
Sometimes surgery is performed first, sometimes only after a few chemotherapy cycles ("interval debulking"). This is determined on the basis of imaging and overall health.
ResearchediPositive results in clinical studies, not yet standard treatment
So-called HIPEC (hyperthermic intraperitoneal chemotherapy) — in which warm chemotherapy fluid is injected directly into the peritoneum during surgery — is being investigated in some centers as a supplement. The aim is to better reach cancer sites in the abdominal and pelvic region. Studies are ongoing; it is not standard and is not offered everywhere.
Chemotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
After surgery, nearly all patients receive chemotherapy intravenously, usually based on platinum (carboplatin or cisplatin) and taxane (paclitaxel). This has been the "gold standard" regimen for decades. Treatment typically lasts 6 cycles, given at approximately 3-week intervals.
Platinum works by causing DNA damage in rapidly dividing cells. Taxanes inhibit cell division. Together they are more effective than either alone. Side effects are part of this treatment: nausea, fatigue, hair loss, reduced blood cells (susceptibility to infection, bruising, pallor), nerve pain in hands and feet, and hearing problems. These symptoms usually gradually disappear after treatment, but some persist longer.
Patients with advanced disease may sometimes benefit from intra-abdominal chemotherapy (directly into the peritoneum), although this is not generally given.
PARP inhibitors as maintenance therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
PARP inhibitors (olaparib, niraparib, rucaparib and others) are an important development. They inhibit an enzyme that helps cells repair damaged DNA. They work particularly well in tumors with BRCA mutations (hereditary defects in DNA repair) or similar abnormalities.
These drugs are usually given after chemotherapy as "maintenance treatment" to delay disease recurrence. The duration varies: sometimes a few months, sometimes years. Studies show that the disease-free interval is extended.
Side effects include fatigue, nausea, digestive problems, and in particular risk of anemia. Regular blood tests are necessary. A small number of patients develop secondary cancer after prolonged exposure.
ResearchediPositive results in clinical studies, not yet standard treatment
Studies are investigating whether PARP inhibitors can help again in patients who were previously treated with them and have now had recurrence. Multicenter studies suggest benefit, especially if treatment was long ago. This occurs outside standard treatment and is discussed on a case-by-case basis.
Bevacizumab (angiogenesis inhibitor)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Bevacizumab inhibits the growth of new blood vessels that supply the tumor. It is given alongside or after chemotherapy, particularly in advanced stages.
Side effects occur with nearly all VEGF inhibitors: elevated blood pressure, protein excretion in urine, thrombosis (blood clots), and rarely bowel perforation. Regular monitoring of blood pressure and urine is necessary.
Immunotherapy
ResearchediPositive results in clinical studies, not yet standard treatment
Immune checkpoint inhibitors (such as pembrolizumab, nivolumab) help the immune system recognize cancer better. They are being studied in combination with chemotherapy or PARP inhibitors.
Studies are ongoing; some patients benefit, others do not. It is not yet standard, but under active investigation, especially for certain tumor types (for example in high microsatellite instability).
Targeted at mutations in tumor DNA
ResearchediPositive results in clinical studies, not yet standard treatment
Tumors can have specific mutations (BRCA1, BRCA2, HRD status, KRAS, TP53) that can be informative. For some mutations, targeted drugs are being developed and tested — for example drugs that target AKT1 mutations or other pathways.
This is mainly a research area. Tumor genotyping is increasingly recommended in more centers to inform future treatment choices.
Working towards treatment outcomes
ProveniIncluded in official guidelines, or approved by EMA or FDA
It is established that completion of the full treatment course (all chemotherapy cycles) is important for outcome. Studies show that patients who stop early have worse prospects. Support with side effects (nausea, fatigue, psychological burden) helps perseverance.
Regular follow-up monitoring with blood tests, imaging and clinical examination is standard to detect recurrence early.
Treatment at recurrence
ProveniIncluded in official guidelines, or approved by EMA or FDA
When cancer recurs, follow-up treatment depends on:
- **How long after the previous chemotherapy**: more than 6 months = "platinum-sensitive" (more treatable); less than 6 months = "platinum-resistant" (limited options).
- **Previous treatment**: was PARP given before? Was bevacizumab used?
In platinum-sensitive recurrence, patients receive platinum chemotherapy again, often followed by PARP inhibitor. In platinum-resistant recurrence, choices are more limited; some chemotherapy drugs have limited evidence, and clinical trials are considered.
ResearchediPositive results in clinical studies, not yet standard treatment
For certain groups (for example low microsatellite instability, certain genomic signatures), combinations of immunotherapy and chemotherapy or other experimental approaches are being tested.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._